The relationship between multiple plasma biomarker levels and renal disease activity in Fabry disease

被引：0
|
作者：
Seyda Gul Ozcan [1 ]
Necmi Eren [2 ]
Mevlut Tamer Dincer [1 ]
Zeynep Atli [3 ]
Murat Bolayirli [4 ]
Metin Ergul [2 ]
Hakan Ozer [5 ]
Kultigin Turkmen [5 ]
Sinan Trabulus [1 ]
Nurhan Seyahi [1 ]
机构：
[1] Istanbul University- Cerrahpasa,Cerrahpasa Medical Faculty, Department of Nephrology
[2] Kocaeli University,Kocaeli Medical Faculty, Department of Nephrology
[3] Sinop University,Deparment of Accounting and Taxation
[4] Istanbul University- Cerrahpasa,Cerrahpasa Medical Faculty, Department of Biochemistry
[5] Necmettin Erbakan University,Meram Medical Faculty, Department of Nephrology
来源：
BMC Nephrology | / 26卷 / 1期
关键词：
Fabry disease; Plasma biomarkers; Genetic kidney disease;
D O I：
10.1186/s12882-025-04189-x
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Prevalence of renal damage previous to the diagnosis of Fabry disease in Argentina
    Jaurretche, Sebastian
    Antongiovanni, Norberto
    Perretta, Fernando
    REVISTA DE NEFROLOGIA DIALISIS Y TRASPLANTE, 2022, 42 (03): : 215 - 224
  • [42] Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease
    Moura, Alana Pimentel
    Hammerschmidt, Tatiane
    Deon, Marion
    Giugliani, Roberto
    Vargas, Carmen Regla
    CLINICA CHIMICA ACTA, 2018, 478 : 62 - 67
  • [43] A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease
    Talbot, Andrew
    Nicholls, Kathy
    Fletcher, Janice M.
    Fuller, Maria
    MOLECULAR GENETICS AND METABOLISM, 2017, 122 (1-2) : 121 - 125
  • [44] Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease
    Aoyama, Yumi
    Ushio, Yusuke
    Yokoyama, Takashi
    Taneda, Sekiko
    Makabe, Shiho
    Nishida, Miki
    Manabe, Shun
    Sato, Masayo
    Kataoka, Hiroshi
    Tsuchiya, Ken
    Nitta, Kosaku
    Mochizuki, Toshio
    INTERNAL MEDICINE, 2020, 59 (07) : 971 - 976
  • [45] Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease
    Pastores, Gregory M.
    Boyd, Ellen
    Crandall, Kerry
    Whelan, Alison
    Piersall, Linda
    Barnett, Natalie
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (07) : 1920 - 1925
  • [46] Screening for Fabry disease in male patients with end-stage renal disease in western France
    Vigneau, C.
    Germain, D. P.
    Larmet, D.
    Jabbour, F.
    Hourmant, M.
    NEPHROLOGIE & THERAPEUTIQUE, 2021, 17 (03): : 180 - 184
  • [47] Fabry disease:: D313Y is an α-galactosidase A sequence variant that causes pseudodeficient activity in plasma
    Froissart, R
    Guffon, N
    Vanier, MT
    Desnick, RJ
    Maire, I
    MOLECULAR GENETICS AND METABOLISM, 2003, 80 (03) : 307 - 314
  • [48] Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry
    Auray-Blais, Christiane
    Blais, Catherine-Marie
    Ramaswami, Uma
    Boutin, Michel
    Germain, Dominique P.
    Dyack, Sarah
    Bodamer, Olaf
    Pintos-Morell, Guillem
    Clarke, Joe T. R.
    Bichet, Daniel G.
    Warnock, David G.
    Echevarria, Lucia
    West, Michael L.
    Lavoie, Pamela
    CLINICA CHIMICA ACTA, 2015, 438 : 195 - 204
  • [49] Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease
    Feriozzi, Sandro
    Schwarting, Andreas
    Sunder-Plassmann, Gere
    West, Michael
    Cybulla, Markus
    AMERICAN JOURNAL OF NEPHROLOGY, 2009, 29 (05) : 353 - 361
  • [50] A Renal Variant of Fabry Disease Diagnosed by the Presence of Urinary Mulberry Cells
    Shimohata, Homare
    Ogawa, Yujiro
    Maruyama, Hiroshi
    Hirayama, Kouichi
    Kobayashi, Masaki
    INTERNAL MEDICINE, 2016, 55 (23) : 3475 - 3478
12345